Publications by authors named "Adolfo Del Canto"
Article Synopsis
- The study investigates the safety and effectiveness of ocrelizumab in Hispanic/Latino individuals with multiple sclerosis (MS), highlighting the need for real-world data from underrepresented populations in clinical trials.
- Out of 305 participants, the majority had relapsing-remitting MS, and the results showed minimal relapses and a significant reduction in MRI activity, with only 12.4% experiencing confirmed disability worsening.
- While the treatment was largely safe, with a low rate of serious infections and a consistent profile of outcomes, the study confirms ocrelizumab's effectiveness in this demographic at a specialized MS center.
Introduction: Multiple Sclerosis (MS) is a chronic disease affecting around 2.8 million people worldwide. Two-thirds are women, and the mean age at diagnosis is about 30 years old.
View Article and Find Full Text PDFBackground: Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease (MOGAD) is an emerging disorder recognized as a clinical entity distinct from Multiple Sclerosis and Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorders (NMOSD-AQP4+), and its phenotypic spectrum continues to expand. Most information about its clinical course has emerged from retrospective studies, and treatment response both in acute and chronic-relapsing disease is still limited. We aimed to describe the clinical and paraclinical characteristics of monophasic and relapsing, paediatric and adult patients with MOGAD under regular clinical care in Chile, highlighting some challenging cases that are far from being considered benign.
View Article and Find Full Text PDF